[The surgery after. . . retroperitoneal lymph node dissection and surgery of the residual masses after chemotherapy for advanced testicular cancer]

Bull Cancer. 2011 Jan;98(1):43-51. doi: 10.1684/bdc.2010.1288.
[Article in French]

Abstract

Thirty-six cases of retroperitoneal lymph node dissections for residual mass after chemotherapy for testicular cancer are reported. In a reference center, the recruitment is modified by the severity of the situations related to very big masses, tumors of poor prognosis and resistant tumors. Lymph node dissection is often atypical and surgery of metastatic residual masses is frequent (13 operations). The 8-year global survival remains stable, over 90%. The 5-year cumulated risk of recurrence is 20%, but these situations can be overtaken.

Publication types

  • English Abstract

MeSH terms

  • Adolescent
  • Adult
  • Humans
  • Lymph Node Excision*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Neoplasm, Residual
  • Neoplasms, Germ Cell and Embryonal / drug therapy*
  • Neoplasms, Germ Cell and Embryonal / pathology
  • Neoplasms, Germ Cell and Embryonal / secondary
  • Neoplasms, Germ Cell and Embryonal / surgery*
  • Retroperitoneal Space
  • Seminoma / drug therapy
  • Seminoma / pathology
  • Seminoma / secondary
  • Seminoma / surgery
  • Testicular Neoplasms / drug therapy*
  • Testicular Neoplasms / mortality
  • Testicular Neoplasms / pathology
  • Testicular Neoplasms / surgery*
  • Tumor Burden
  • Young Adult

Supplementary concepts

  • Nonseminomatous germ cell tumor